Symptoms and General Pathology

Wounds and Injuries

All Conditions

Neoplasms

Behaviors and Mental Disorders

Hyperthermia

Fever

Carcinoma

Body Temperature Changes

Stress Disorders, Traumatic

Heat Stress Disorders

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Antineoplastic Agents

All Drugs and Chemicals

Micronutrients

Hematinics

Pharmaceutical Solutions

Vitamins

Irinotecan

Leucovorin

Fluorouracil

Levoleucovorin

Folic Acid

Dialysis Solutions

Mitomycins

Mitomycin

Folinic Acid

Folate

Vitamin B9

The most complete cytoreductive surgery possible (ideally macroscopically complete) followed by a closed-abdomen hyperthermic intraoperative peritoneal chemotherapy (HIPEC), using a closed circuit connected to the self-regulating Cavitherm machine (EEC certified). This perfusion apparatus records temperature, flow, and pressure for 90 minutes at real temperature (42-43°C).

The dialysate is made up of peritoneal dialysis fluid containing 0.7 mg/kg of MMC and increasing doses of irinotecan added to the dialysate the last 30 minutes of the HIPEC.

Potentiation of irinotecan using an intravenous FUFOL perfusion at least 1hour before HIPEC (1st dose level: 10 mg/m² of folinic acid, then 200 mg/m² of 5-FU; 2nd dose level: 20 mg/m² of folinic acid, then 400 mg/m² of 5-FU).

cytoreductive surgery and HIPEC

This is an open, non-randomized, phase I-II, pilot study, which evaluates the combination of optimum cytoreductive surgery and hyperthermic intraoperative peritoneal chemotherapy (HIPEC) with mitomycin C (MMC) and irinotecan. The latter drug will be administered in escalating doses to patients with gastric, colorectal, appendicular, or primary peritoneal carcinosis (PC).

Treatment of Primary Peritoneal Carcinosis of Digestive Origin Using Cytoreductive Surgery and Hyperthermic Intraoperative Peritoneal Chemotherapy With Mitomycin C and Irinotecan

postoperative complications (class III and IV, Common Terminology Criteria V3; National Cancer Institute)

Plasma, peritoneal, and urinary values for MMC, irinotecan, SN-38, SN-38G, APC, and NPC.

Hospices Civils de Lyon

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Treatment of Primary Peritoneal Carcinosis of Digestive Origin Using Cytoreductive Surgery and Hyperthermic Intraoperative Peritoneal Chemotherapy With Mitomycin C and Irinotecan	NCT01226550	Peritoneal Carc...	cytoreductive s...	18 Years - 64 Years	Hospices Civils de Lyon
Treatment of Primary Peritoneal Carcinosis of Digestive Origin Using Cytoreductive Surgery and Hyperthermic Intraoperative Peritoneal Chemotherapy With Mitomycin C and Irinotecan	NCT01226550	Peritoneal Carc...	cytoreductive s...	18 Years - 64 Years	Hospices Civils de Lyon

Spots Global Cancer Trial Database for peritoneal carcinosis (pc)